Skip to main content

Advertisement

ADVERTISEMENT

Clinical Trial Update

Safety and Efficacy Findings from the SPIRIT 48 Trial of the Xience 48 mm Drug-Eluting Stent

Ki Park, MD, MS, FACC, FSCAI, Associate Professor of Medicine in the Division of Cardiovascular Medicine at the University of Florida, and lead researcher of the SPIRIT 48 Trial.

05/19/2023

The prospective, single-arm, open-label SPIRIT 48 trial evaluated the safety and efficacy of the Xience Skypoint 48 mm drug-eluting stent (Abbott Vascular) in subjects with coronary artery disease with long de novo native coronary lesions.

Lead researcher Dr. Ki Park discusses the trial and next steps.

 


Advertisement

Advertisement

Advertisement